Recent genomic profiling studies confirmed a high frequency of TP53 mutations in de novo and ex PA SDCs [2, 3], affecting about 50% of the tumors, pointing to an outstanding relevance of the p53 tumor suppressing network in the pathogenesis of these rare but highly aggressive tumors. The gene discussed is TP53; the disease is neoplasm.